Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Breast Cancer

Free Subscription Articles published in Lancet Oncol Retrieve available abstracts of 67 articles: HTML format

Single Articles

April 2026
1. PROWSE J
   European Breast Cancer Conference 2026.
   Lancet Oncol. 2026 Apr 2:S1470-2045(26)00173.
   PubMed    
   
   
   March 2026
2. SHAMAI G, Cohen S, Binenbaum Y, Sabo E, et al
   Deep learning on histopathological images to predict breast cancer recurrence risk and chemotherapy benefit: a multicentre, model development and validation study.
   Lancet Oncol. 2026 Mar 11:S1470-2045(25)00727.
   PubMed     Abstract available
   
   
   
3. LIU J, Liu Y, Song E, Li H, et al
   Fuzuloparib plus apatinib in BRCA-mutated breast cancer: balancing efficacy and accessibility in regional China - Authors' reply.
   Lancet Oncol. 2026;27:e126.
   PubMed    
   
   
   
4. QIU Z, Jin N
   Fuzuloparib plus apatinib in BRCA-mutated breast cancer: balancing efficacy and accessibility in regional China.
   Lancet Oncol. 2026;27:e125.
   PubMed    
   
   
   
5. 
   Global, regional, and national burden of breast cancer among females, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.
   Lancet Oncol. 2026;27:302-326.
   PubMed     Abstract available
   
   
   
6. PARK YH
   Beyond regional boundaries: crucial gaps in global breast cancer burden estimates.
   Lancet Oncol. 2026;27:270-271.
   PubMed    
   
   
   February 2026
7. NADER-MARTA G, Mayer EL
   Towards response-adapted neoadjuvant breast cancer treatment.
   Lancet Oncol. 2026 Feb 16:S1470-2045(25)00767.
   PubMed    
   
   
   
8. LOUIS FM, van der Voort A, van Ramshorst MS, Daletzakis A, et al
   MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study.
   Lancet Oncol. 2026 Feb 16:S1470-2045(25)00707.
   PubMed     Abstract available
   
   
   January 2026
9. MONTAGNA G, Alvarado M, Myers S, Mrdutt MM, et al
   Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study.
   Lancet Oncol. 2026;27:57-67.
   PubMed     Abstract available
   
   
   December 2025
10. PATODIA S
    San Antonio Breast Cancer Symposium 2025.
    Lancet Oncol. 2025 Dec 18:S1470-2045(25)00753.
    PubMed    
    
    
    
11. PFOB A, Pinker K, Vaz-Luis I, Di Meglio A, et al
    The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer-a multidisciplinary consensus.
    Lancet Oncol. 2025;26:e694-e706.
    PubMed     Abstract available
    
    
    
12. CONFORTI F, Holtschmidt J, Nekljudova V, Sala I, et al
    Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials.
    Lancet Oncol. 2025;26:1584-1597.
    PubMed     Abstract available
    
    
    
13. YUAN J, Bi XW, Hua X, Huang H, et al
    Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial.
    Lancet Oncol. 2025;26:1575-1583.
    PubMed     Abstract available
    
    
    
14. LI H, Liu J, Ouyang Q, Wang S, et al
    Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial.
    Lancet Oncol. 2025;26:1563-1574.
    PubMed     Abstract available
    
    
    
15. SIKOV WM
    Adjuvant capecitabine in early-stage triple-negative breast cancer? Yes, but for whom?
    Lancet Oncol. 2025;26:1515-1517.
    PubMed    
    
    
    November 2025
16. BARTSCH R, Marhold M, Garde-Noguera J, Gion M, et al
    Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial.
    Lancet Oncol. 2025;26:1467-1478.
    PubMed     Abstract available
    
    
    October 2025
17. SAVAS P, Loi S
    Whole-genome sequencing in breast cancer: is it ready for clinical application?
    Lancet Oncol. 2025 Oct 7:S1470-2045(25)00428.
    PubMed    
    
    
    
18. BLACK D, Davies HR, Koh GCC, Chmelova L, et al
    Clinical potential of whole-genome data linked to mortality statistics in patients with breast cancer in the UK: a retrospective analysis.
    Lancet Oncol. 2025 Oct 7:S1470-2045(25)00400.
    PubMed     Abstract available
    
    
    
19. BIRRELL SN
    Synthetic progestin use and young-onset breast cancer.
    Lancet Oncol. 2025;26:e516.
    PubMed    
    
    
    July 2025
20. GOURD E
    New test for breast cancer set to transform patient treatment.
    Lancet Oncol. 2025 Jul 24:S1470-2045(25)00461.
    PubMed    
    
    
    
21. VILLACAMPA G, Pascual T, Tarantino P, Cortes J, et al
    HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis.
    Lancet Oncol. 2025 Jul 14:S1470-2045(25)00276.
    PubMed     Abstract available
    
    
    
22. LAYMAN RM, Han HS, Rugo HS, Stringer-Reasor EM, et al
    Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy.
    Lancet Oncol. 2025;26:e332-e333.
    PubMed    
    
    
    
23. O'BRIEN KM, House MG, Goldberg M, Jones ME, et al
    Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group.
    Lancet Oncol. 2025;26:911-923.
    PubMed     Abstract available
    
    
    
24. LEVY C
    Hormonal therapy for young-onset breast cancer: current understanding and lessons.
    Lancet Oncol. 2025;26:824-825.
    PubMed    
    
    
    June 2025
25. SAITO M, Iihara H, Shimokawa M, Udagawa R, et al
    Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial.
    Lancet Oncol. 2025 Jun 17:S1470-2045(25)00233.
    PubMed     Abstract available
    
    
    
26. KIRBY AM, Finneran L, Griffin CL, Brunt AM, et al
    Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial.
    Lancet Oncol. 2025 Jun 11:S1470-2045(25)00194.
    PubMed     Abstract available
    
    
    May 2025
27. HASSAN H, Allen I, Rahman T, Allen S, et al
    Long-term health outcomes of bilateral salpingo-oophorectomy in BRCA1 and BRCA2 pathogenic variant carriers with personal history of breast cancer: a retrospective cohort study using linked electronic health records.
    Lancet Oncol. 2025 May 7:S1470-2045(25)00156.
    PubMed     Abstract available
    
    
    
28. BLONDEAUX E, Sonnenblick A, Agostinetto E, Bas R, et al
    Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study.
    Lancet Oncol. 2025 May 7:S1470-2045(25)00152.
    PubMed     Abstract available
    
    
    
29. ESCRIVA-DE-ROMANI S, Cejalvo JM, Alba E, Friedmann J, et al
    Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study.
    Lancet Oncol. 2025 May 5:S1470-2045(25)00140.
    PubMed     Abstract available
    
    
    
30. JENSEN MB, Torpe E, Teunissen Z, Taarnhoj G, et al
    Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early breast cancer: a nationwide, prospective cohort study by the Danish Breast Cancer Group.
    Lancet Oncol. 2025;26:654-662.
    PubMed     Abstract available
    
    
    
31. KUEMMEL S, Graeser M, Schmid P, Reinisch M, et al
    Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial.
    Lancet Oncol. 2025;26:629-640.
    PubMed     Abstract available
    
    
    
32. GRUBER K
    Monstrosity of Tiny Tumours: an artist's journey through breast cancer.
    Lancet Oncol. 2025;26:558.
    PubMed    
    
    
    March 2025
33. DEVI S
    Projected global rise in breast cancer incidence and mortality by 2050.
    Lancet Oncol. 2025 Mar 6:S1470-2045(25)00136.
    PubMed    
    
    
    
34. ZDENKOWSKI N, Kuper-Hommel MJJ, Niman SM, Francis PA, et al
    Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial.
    Lancet Oncol. 2025;26:367-377.
    PubMed     Abstract available
    
    
    
35. MAGSANOC-ALIKPALA MJK, Ylanan AMD, Rivera-Montales C, Magsanoc JM, et al
    Breast cancer survivor-led patient advocacy: the ICanServe experience from the Philippines.
    Lancet Oncol. 2025;26:287-289.
    PubMed    
    
    
    
36. GONCALVES A, de Nonneville A
    Tailoring chemoimmunotherapy de-escalation in early-stage triple-negative breast cancer.
    Lancet Oncol. 2025;26:273-274.
    PubMed    
    
    
    February 2025
37. AHN HK, Kim JY, Lee KH, Kim GM, et al
    Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study.
    Lancet Oncol. 2025 Feb 17:S1470-2045(25)00006.
    PubMed     Abstract available
    
    
    
38. MUNZONE E, Valenza C
    Tailoring the treatment of premenopausal patients with breast cancer.
    Lancet Oncol. 2025 Feb 17:S1470-2045(25)00060.
    PubMed    
    
    
    
39. BONNEFOI H, Lerebours F, Pulido M, Arnedos M, et al
    Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial.
    Lancet Oncol. 2025 Feb 17:S1470-2045(24)00737.
    PubMed     Abstract available
    
    
    
40. SRIDHAR N, Ueno NT
    Navigating the androgen receptor landscape in triple-negative breast cancer.
    Lancet Oncol. 2025 Feb 17:S1470-2045(25)00029.
    PubMed    
    
    
    
41. VENKATESAN P
    Largest trial of AI in breast cancer screening launched.
    Lancet Oncol. 2025 Feb 13:S1470-2045(25)00080.
    PubMed    
    
    
    
42. CASASSUS B
    Law to extend free medical treatment for breast cancer in France.
    Lancet Oncol. 2025 Feb 6:S1470-2045(25)00069.
    PubMed    
    
    
    January 2025
43. LI L
    FNAB samples with the STRAT4 assay for breast cancer diagnosis.
    Lancet Oncol. 2025;26:e9.
    PubMed    
    
    
    
44. NG DL, Van Loon K, Weidler J, Bates M, et al
    FNAB samples with the STRAT4 assay for breast cancer diagnosis - Authors' reply.
    Lancet Oncol. 2025;26:e10.
    PubMed    
    
    
    December 2024
45. GRUBER K
    Pesticide exposure and increased risk of breast cancer for women in rural Brazil.
    Lancet Oncol. 2024 Dec 19:S1470-2045(24)00726.
    PubMed    
    
    
    
46. HENRY NL
    Optimising therapy and avoiding overtreatment in breast cancer.
    Lancet Oncol. 2024 Dec 11:S1470-2045(24)00707.
    PubMed    
    
    
    
47. MEATTINI I, De Santis MC, Visani L, Scorsetti M, et al
    Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial.
    Lancet Oncol. 2024 Dec 11:S1470-2045(24)00661.
    PubMed     Abstract available
    
    
    
48. RUGO HS, Lerebours F, Ciruelos E, Drullinsky P, et al
    Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
    Lancet Oncol. 2024;25:e629-e638.
    PubMed     Abstract available
    
    
    November 2024
49. CHEN XC, Jiao DC, Qiao JH, Wang CZ, et al
    De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial.
    Lancet Oncol. 2024 Nov 26:S1470-2045(24)00581.
    PubMed     Abstract available
    
    
    
50. LUND M, Corn G, Jensen MB, Petersen T, et al
    Ischaemic cardiotoxicity of aromatase inhibitors in postmenopausal patients with early breast cancer in Denmark: a cohort study of real-world data.
    Lancet Oncol. 2024;25:1496-1506.
    PubMed     Abstract available
    
    
    
51. OLIVEIRA M, Pominchuk D, Nowecki Z, Hamilton E, et al
    Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial.
    Lancet Oncol. 2024;25:1424-1439.
    PubMed     Abstract available
    
    
    October 2024
52. NG DL, Vuhahula E, Kimambo AH, Ndayisaba MC, et al
    Xpert Breast Cancer STRAT4 Assay using fine-needle aspiration biopsy samples in a resource-constrained setting: a prospective diagnostic accuracy study.
    Lancet Oncol. 2024 Oct 3:S1470-2045(24)00456.
    PubMed     Abstract available
    
    
    September 2024
53. OLIVEIRA M, Rugo HS, Howell SJ, Dalenc F, et al
    Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.
    Lancet Oncol. 2024;25:1231-1244.
    PubMed     Abstract available
    
    
    
54. KOLBERG HC, Kolberg-Liedtke C
    Who does not benefit from whole-breast radiotherapy and how to find them?
    Lancet Oncol. 2024;25:1110-1111.
    PubMed    
    
    
    
55. DE BONIFACE J, Appelgren M, Szulkin R, Alkner S, et al
    Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial.
    Lancet Oncol. 2024;25:1222-1230.
    PubMed     Abstract available
    
    
    August 2024
56. GOURD E
    Disappointment facing patients with breast cancer as trastuzumab deruxtecan too expensive for NHS.
    Lancet Oncol. 2024 Aug 8:S1470-2045(24)00446.
    PubMed    
    
    
    
57. WILLIAMS LJ, Kunkler IH, Taylor KJ, Dunlop J, et al
    Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial.
    Lancet Oncol. 2024 Aug 7:S1470-2045(24)00347.
    PubMed     Abstract available
    
    
    
58. BARRIO AV
    Time to abandon axillary lymph node dissection in early-stage breast cancer.
    Lancet Oncol. 2024 Aug 6:S1470-2045(24)00385.
    PubMed    
    
    
    July 2024
59. OFUYA M
    Overcoming barriers to early breast cancer presentation in Nigeria.
    Lancet Oncol. 2024;25:840.
    PubMed    
    
    
    
60. GOURD E
    Olufunmilayo Olopade-preventive oncologist using genetics to fight breast cancer in high-risk populations.
    Lancet Oncol. 2024;25:839.
    PubMed    
    
    
    
61. PELLERIN R
    New Canadian draft breast screening guidelines issued.
    Lancet Oncol. 2024;25:836.
    PubMed    
    
    
    May 2024
62. FEHM T, Cottone F, Dunton K, Andre F, et al
    Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
    Lancet Oncol. 2024;25:614-625.
    PubMed     Abstract available
    
    
    April 2024
63. VAN DER VOORT A, Louis FM, van Ramshorst MS, Kessels R, et al
    MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.
    Lancet Oncol. 2024 Apr 5:S1470-2045(24)00104.
    PubMed     Abstract available
    
    
    
64. BROWNE IM, Andre F, Chandarlapaty S, Carey LA, et al
    Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer.
    Lancet Oncol. 2024;25:e139-e151.
    PubMed     Abstract available
    
    
    
65. LAYMAN RM, Han HS, Rugo HS, Stringer-Reasor EM, et al
    Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
    Lancet Oncol. 2024;25:474-487.
    PubMed     Abstract available
    
    
    March 2024
66. TOI M, Kinoshita T, Benson JR, Jatoi I, et al
    Non-surgical ablation for breast cancer: an emerging therapeutic option.
    Lancet Oncol. 2024;25:e114-e125.
    PubMed     Abstract available
    
    
    October 2023
67. MUTTER RW, Giri S, Fruth BF, Remmes NB, et al
    Conventional versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trial.
    Lancet Oncol. 2023;24:1083-1093.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum